# OnCo record paper-denmeade-transformer-bipolar-androgen-therapy-jco-2021 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-denmeade-transformer-bipolar-androgen-therapy-jco-2021/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-denmeade-transformer-bipolar-androgen-therapy-jco-2021" ;
  schema:name "TRANSFORMER: bipolar androgen therapy versus enzalutamide in asymptomatic metastatic castration-resistant prostate cancer"@en ;
  schema:alternateName "TRANSFORMER"@en, "Denmeade 2021 bipolar androgen therapy randomised"@en ;
  schema:description "A randomised comparison of high-dose testosterone against a standard hormone-blocking drug. Neither delayed progression better than the other, but men who had the testosterone first and the drug second lived nearly nine months longer before their second progression, and felt better throughout."@en ;
  schema:url <https://onco.cc/key-papers/paper-denmeade-transformer-bipolar-androgen-therapy-jco-2021/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://doi.org/10.1200/jco.20.02759>, <https://pubmed.ncbi.nlm.nih.gov/33617303/>, <https://clinicaltrials.gov/study/NCT02286921> ;
  onco:tag "prostate-evidence" ;
  schema:sameAs <https://doi.org/10.1200/jco.20.02759> ;
  schema:datePublished "2021"^^xsd:gYear ;
  schema:author "Denmeade SR, Wang H, Agarwal N, et al." ;
  onco:related <https://onco.cc/key-papers/paper-teply-restore-bipolar-androgen-therapy-lancet-oncol-2018/>, <https://onco.cc/key-papers/paper-hussain-swog-9346-intermittent-androgen-deprivation-nejm-2013/>, <https://onco.cc/ideas/idea-tr1-adaptive-therapy-randomised-phase-2/>, <https://onco.cc/roadmaps/prostate-roadmap/> ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mcrpc/> ;
  onco:sections <https://onco.cc/fronts/hormonal/> ;
  onco:targets <https://onco.cc/targets/androgen-receptor/> ;
  onco:drugs <https://onco.cc/drugs/enzalutamide/>, <https://onco.cc/drugs/abiraterone/> ;
  onco:institutions <https://onco.cc/institutions/johns-hopkins/> ;
  onco:terms <https://onco.cc/terms/castration-resistance/>, <https://onco.cc/terms/psa/>, <https://onco.cc/terms/quality-of-life/>, <https://onco.cc/terms/bipolar-androgen-therapy/>, <https://onco.cc/terms/radiographic-progression-free-survival/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-resistance/>, <https://onco.cc/bottlenecks/b-trial-design/>, <https://onco.cc/bottlenecks/b-toxicity-qol/> ;
  onco:journals <https://onco.cc/journals/jco/> .